HIF-1α is required for disturbed flow-induced metabolic reprogramming in human and porcine vascular endothelium

  1. David Wu
  2. Ru-Ting Huang
  3. Robert B Hamanaka
  4. Matthew D Krause
  5. Myung-Jin Oh
  6. Cheng-Hsiang Kuo
  7. Recep Nigdelioglu
  8. Angelo Y Meliton
  9. Leah Witt
  10. Guohao Dai
  11. Mete Civelek
  12. Nanduri R Prabhakar
  13. Yun Fang  Is a corresponding author
  14. Gökhan M Mutlu  Is a corresponding author
  1. The University of Chicago, United States
  2. Northeastern University, United States
  3. University of Virginia, United States

Abstract

Hemodynamic forces regulate vascular functions. Disturbed flow (DF) occurs in arterial bifurcations and curvatures, activates endothelial cells (ECs), and results in vascular inflammation and ultimately atherosclerosis. However, how DF alters EC metabolism, and whether resulting metabolic changes induce EC activation, is unknown. Using transcriptomics and bioenergetic analysis, we discovered that DF induces glycolysis and reduces mitochondrial respiratory capacity in human aortic ECs. DF-induced metabolic reprogramming required hypoxia inducible factor-1α (HIF-1α), downstream of NAD(P)H oxidase-4 (NOX4)-derived reactive oxygen species (ROS). HIF-1α increased glycolytic enzymes and pyruvate dehydrogenase kinase-1 (PDK-1), which reduces mitochondrial respiratory capacity. Swine aortic arch endothelia exhibited elevated ROS, NOX4, HIF-1α, and glycolytic enzyme and PDK1 expression, suggesting that DF leads to metabolic reprogramming in vivo. Inhibition of glycolysis reduced inflammation suggesting a causal relationship between flow-induced metabolic changes and EC activation. These findings highlight a previously uncharacterized role for flow-induced metabolic reprogramming and inflammation in ECs.

Data availability

The following data sets were generated

Article and author information

Author details

  1. David Wu

    Department of Medicine, The University of Chicago, Chicago, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3162-3238
  2. Ru-Ting Huang

    Department of Medicine, The University of Chicago, Chicago, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Robert B Hamanaka

    Department of Medicine, The University of Chicago, Chicago, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8909-356X
  4. Matthew D Krause

    Department of Medicine, The University of Chicago, Chicago, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Myung-Jin Oh

    Department of Medicine, The University of Chicago, Chicago, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Cheng-Hsiang Kuo

    Department of Medicine, The University of Chicago, Chicago, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4885-9020
  7. Recep Nigdelioglu

    Department of Medicine, The University of Chicago, Chicago, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Angelo Y Meliton

    Department of Medicine, The University of Chicago, Chicago, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Leah Witt

    Department of Medicine, The University of Chicago, Chicago, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Guohao Dai

    Department of Bioengineering, Northeastern University, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Mete Civelek

    Department of Biomedical Engineering, University of Virginia, Charlottesville, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Nanduri R Prabhakar

    Institute for Integrative Physiology, The University of Chicago, Chicago, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Yun Fang

    Department of Medicine, The University of Chicago, Chicago, United States
    For correspondence
    yfang1@medicine.bsd.uchicago.edu
    Competing interests
    The authors declare that no competing interests exist.
  14. Gökhan M Mutlu

    Department of Medicine, The University of Chicago, Chicago, United States
    For correspondence
    gmutlu@medicine.bsd.uchicago.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2056-612X

Funding

National Institutes of Health (T32HL007605)

  • David Wu
  • Myung-Jin Oh

American Heart Association (15POST255900003)

  • Recep Nigdelioglu

National Institutes of Health (F32HL134288)

  • David Wu

National Institutes of Health (R21ES025644)

  • Gökhan M Mutlu

National Institutes of Health (K01AR066579)

  • Robert B Hamanaka

National Institutes of Health (R01ES015024)

  • Gökhan M Mutlu

National Institutes of Health (P01HL090554)

  • Nanduri R Prabhakar

National Institutes of Health (R00HL103789)

  • Yun Fang

American Heart Association (BGIA7080012)

  • Yun Fang

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All procedures were in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The use of vertebrate animal tissues was approved by the Animal Care and Use Committee of the University of Chicago (Permit # 72281). The use of vertebrate animal tissues obtained from outside the University of Chicago was approved by the Animal Care and Use Committee of the University of Chicago (Permit # 72500).

Copyright

© 2017, Wu et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,940
    views
  • 714
    downloads
  • 134
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. David Wu
  2. Ru-Ting Huang
  3. Robert B Hamanaka
  4. Matthew D Krause
  5. Myung-Jin Oh
  6. Cheng-Hsiang Kuo
  7. Recep Nigdelioglu
  8. Angelo Y Meliton
  9. Leah Witt
  10. Guohao Dai
  11. Mete Civelek
  12. Nanduri R Prabhakar
  13. Yun Fang
  14. Gökhan M Mutlu
(2017)
HIF-1α is required for disturbed flow-induced metabolic reprogramming in human and porcine vascular endothelium
eLife 6:e25217.
https://doi.org/10.7554/eLife.25217

Share this article

https://doi.org/10.7554/eLife.25217

Further reading

    1. Cell Biology
    2. Immunology and Inflammation
    Daniel M Williams, Andrew A Peden
    Research Article

    NLRP3 is an inflammasome seeding pattern recognition receptor activated in response to multiple danger signals which perturb intracellular homeostasis. Electrostatic interactions between the NLRP3 polybasic (PB) region and negatively charged lipids on the trans-Golgi network (TGN) have been proposed to recruit NLRP3 to the TGN. In this study, we demonstrate that membrane association of NLRP3 is critically dependant on S-acylation of a highly conserved cysteine residue (Cys-130), which traps NLRP3 in a dynamic S-acylation cycle at the Golgi, and a series of hydrophobic residues preceding Cys-130 which act in conjunction with the PB region to facilitate Cys-130 dependent Golgi enrichment. Due to segregation from Golgi localised thioesterase enzymes caused by a nigericin induced breakdown in Golgi organisation and function, NLRP3 becomes immobilised on the Golgi through reduced de-acylation of its Cys-130 lipid anchor, suggesting that disruptions in Golgi homeostasis are conveyed to NLRP3 through its acylation state. Thus, our work defines a nigericin sensitive S-acylation cycle that gates access of NLRP3 to the Golgi.

    1. Cell Biology
    2. Neuroscience
    Luting Yang, Chunqing Hu ... Yaping Yan
    Research Article

    Reactive astrocytes play critical roles in the occurrence of various neurological diseases such as multiple sclerosis. Activation of astrocytes is often accompanied by a glycolysis-dominant metabolic switch. However, the role and molecular mechanism of metabolic reprogramming in activation of astrocytes have not been clarified. Here, we found that PKM2, a rate-limiting enzyme of glycolysis, displayed nuclear translocation in astrocytes of EAE (experimental autoimmune encephalomyelitis) mice, an animal model of multiple sclerosis. Prevention of PKM2 nuclear import by DASA-58 significantly reduced the activation of mice primary astrocytes, which was observed by decreased proliferation, glycolysis and secretion of inflammatory cytokines. Most importantly, we identified the ubiquitination-mediated regulation of PKM2 nuclear import by ubiquitin ligase TRIM21. TRIM21 interacted with PKM2, promoted its nuclear translocation and stimulated its nuclear activity to phosphorylate STAT3, NF-κB and interact with c-myc. Further single-cell RNA sequencing and immunofluorescence staining demonstrated that TRIM21 expression was upregulated in astrocytes of EAE. TRIM21 overexpressing in mice primary astrocytes enhanced PKM2-dependent glycolysis and proliferation, which could be reversed by DASA-58. Moreover, intracerebroventricular injection of a lentiviral vector to knockdown TRIM21 in astrocytes or intraperitoneal injection of TEPP-46, which inhibit the nuclear translocation of PKM2, effectively decreased disease severity, CNS inflammation and demyelination in EAE. Collectively, our study provides novel insights into the pathological function of nuclear glycolytic enzyme PKM2 and ubiquitination-mediated regulatory mechanism that are involved in astrocyte activation. Targeting this axis may be a potential therapeutic strategy for the treatment of astrocyte-involved neurological disease.